OakChart

Arcturus Therapeutics Holdings Inc

ARCTHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 10:34 AM ET

9.34-0.06 (-0.59%)
2026-11-11 16:34 CET
Market cap
270.64 USD m
Revenue, TTM
21.42 USD m
Net income, TTM
-87.24 USD m
Free cash flow, TTM
-64.47 USD m
EPS diluted, TTM
-3.08
P/E
-
Compare

Price

ARCT against its 20, 50 and 200-day averages
2050200beat
5.0010.0015.002.8M5.6MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ARCTclose 9.3420-day 10.4450-day 12.74200-day 9.099.3452w high52w low

48.0% under the 52-week high of 17.96 on 17 Sep 2026. 52-week low 5.50 on 24 Jul 2026. Last 15 sessions, 36.3% high to low

Profile

ARCT
52-week range, 31% of the way up
5.5017.96

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

IndexRUT
Employees111
IPOMay 22, 2013
Beta2.62
ATR, 14d1.11
Rel volume0.24
Short float20.48%
Insider own8.36%
Inst own78.65%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap269.05M
Enterprise Value106.09M
Income-87.24M
Sales21.42M
Book/sh5.93
Cash/sh6.41
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees111
IPOMay 22, 2013

Ratios

P/E-
Forward P/E-
PEG-
P/S12.56
P/B1.57
P/C1.46
P/FCF-
EV/EBITDA-
EV/Sales4.95
Quick Ratio6.68
Current Ratio6.68
Debt/Eq0.13
LT Debt/Eq0.11
Option/ShortYes / Yes

Earnings

EPS (ttm)-3.08
EPS next Y-3.55
EPS next Q-0.83
EPS this Y-26.00%
EPS next Y-17.44%
EPS next 5Y-12.37%
EPS past 3/5Y- 7.53%
Sales past 3/5Y-31.15% 47.77%
EPS Y/Y TTM-25.04%
Sales Y/Y TTM-74.84%
EPS Q/Q47.29%
Sales Q/Q19.07%
EarningsNov 05 AMC
EPS/Sales Surpr.62.13% 128.80%

Ownership

Insider Own8.36%
Insider Trans0.00%
Inst Own78.65%
Inst Trans-3.90%
ROA-35.06%
ROE-44.37%
ROIC-46.66%
Gross Margin88.14%
Oper. Margin-463.82%
Profit Margin-407.24%
SMA20-10.61%
SMA50-26.72%
SMA2002.65%
Trades-

Technical

Shs Outstand28.46M
Shs Float26.41M
Short Float20.48%
Short Ratio5.43
Short Interest5.41M
52W High17.96 -48.02%
52W Low5.50 69.73%
Volatility12.17% 10.17%
ATR (14)1.11
RSI (14)41.02
Beta2.62
Rel Volume0.24
Avg Volume996.39K
Volume50,048

Performance

Perf Week-14.12%
Perf Month-22.40%
Perf Quarter18.77%
Perf Half Y13.01%
Perf YTD52.28%
Perf Year7.67%
Perf 3Y-51.28%
Perf 5Y-75.06%
Perf 10Y-31.26%
Recom1.31
Target Price23.80
Prev Close9.39
Price9.34
Change %-0.59%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Sep 24, 2026UpgradeCCitigroupNeutral → Buy$20+114.2%
Mar 18, 2026InitiatedRB. Riley SecuritiesBuy$22+135.7%
Jan 23, 2026InitiatedRRoth CapitalBuy$20+114.2%
Oct 24, 2025DowngradeHH.C. WainwrightBuy → Neutral$12+28.5%
Oct 23, 2025DowngradeCCitigroupBuy → Neutral$12+28.5%
Oct 22, 2025DowngradeGGuggenheimBuy → Neutral
Sep 04, 2025ResumedHH.C. WainwrightBuy$60+542.7%
May 28, 2025InitiatedBScotiabankSector Outperform$32+242.8%
Jan 28, 2025InitiatedBBTIG ResearchBuy$41+339.2%
Aug 12, 2024InitiatedLLeerink PartnersOutperform$70+649.9%

Peers

Mkt cap
TickerCompanyMkt cap
MRNAModerna Inc100.78B
BNTXBioNTech SE ADR21.57B
NVAXNovavax Inc1.66B
FDMT4D Molecular Therapeutics Inc688.73M
RAREUltragenyx Pharmaceutical Inc1.67B
RNACCartesian Therapeutics Inc213.28M
KRYSKrystal Biotech Inc9.03B
EDITEditas Medicine Inc370.41M
VIRVir Biotechnology Inc2.23B
OCGNOcugen Inc313.55M

Held by

AUM
TickerCompanyAUM
ARKGARK Genomic Revolution ETFAUM: 1.97B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IBBiShares Biotechnology ETFAUM: 11.36B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VHTVanguard Health Care ETFAUM: 21.51B
DWASInvesco Dorsey Wright SmallCap Momentum ETFAUM: 391.13M

News

latest 14 of 206
  • Arcturus Beats On A One-Time CSL Windfall, But The Real Story Is A Bigger Pipeline With Later Decision Points (Earnings Whispers) -13.89% +10.58%
  • Arcturus Therapeutics Announces Third Quarter 2026 Financial Results and Pipeline Progress (Business Wire)
  • Arcturus Heads Into Q3 With OTC Data Window Closed And A Rallied Stock Awaiting Proof (Earnings Whispers) +7.48%
  • Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 5, 2026 (Business Wire) +13.32%
  • CoreWeave upgraded, Etsy downgraded: Wall Street's top analyst calls (The Fly) +6.17%
  • Loading…
  • Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0 Next-Generation mRNA Delivery Platform (Business Wire) -7.51%
  • Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform (Business Wire) -5.32%
  • Arcturus Therapeutics to Participate in Upcoming Investor Conferences (Business Wire) +9.93%
  • Can mRNA Cure Cancer? Inside the Pipeline Risks for Biotech's Biggest Players (Barrons.com) +22.38%
  • Why Moderna's mRNA Cancer Drug Hype Has Gone Too Far (Barrons.com)
  • Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress (Business Wire) +21.87%
  • Earnings To Watch: Arcturus Therapeutics Holdings Inc (ARCT) Q2 2026 -- GF Value Sees 44% Downside (GuruFocus.com)
  • Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on Aug 6, 2026 (Business Wire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.260-0.687-0.26018.308.0013
2026Q22026-08-06-0.840-0.996-0.8372.963.1113
2026Q12026-05-07-0.950-1.010-0.9492.066.3013
2025Q42026-03-03-1.030-0.777-1.0347.2015.909
2025Q32025-11-10-0.490-0.899-0.49517.1516.0310
2025Q22025-08-11-0.340-0.892-0.33828.3018.8310
2025Q12025-05-12-0.520-1.178-0.51929.3823.3510
2024Q42025-03-06-1.110-0.549-1.11122.7739.9511
2024Q32024-11-07-0.260-1.216-0.25541.6736.5911
2024Q22024-08-05-0.640-1.498-0.63849.8622.238
2024Q12024-05-08-1.000-1.234-0.99838.0117.679
2023Q42024-03-07-0.320-0.992-0.32233.9937.8610
2023Q32023-11-14-0.610-1.692-0.61045.1415.859
2023Q22023-08-07-1.980-0.245-1.97810.5249.339
2023Q12023-05-091.8700.0601.87080.2937.948
2022Q42023-03-284.330-1.7204.333160.299.756

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-2.150-1.820-2.15420.7921.45
2020FY-3.550-3.016-3.5539.549.76
2021FY-7.740-7.869-7.73912.4023.84
2022FY0.350-5.8320.34520653.87
2023FY-1.000-1.783-1.116169.93173.81
2024FY-3.000-2.432-2.998152.31169.49
2025FY-2.400-2.063-2.40082.0390.77
2026FY--3.024--23.57
2027FY--3.551--24.21
2028FY--3.406--43.85
2029FY--1.086--150.31
2030FY-2.953--332.12

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0613263.961.2010.21
2026Q4S2026-11-0512104.971.9019.73
2026Q4S2026-10-2412104.971.9019.73
2026Q4S2026-10-2112204.971.9019.73
2026Q4S2026-10-0812434.971.9019.73
2026Q4S2026-09-2912434.971.9019.70
2026Q4S2026-09-2412434.971.9019.70
2026Q4S2026-09-2312344.971.9019.70
2026Q4S2026-09-2212434.971.9019.70
2026Q4S2026-08-1612434.971.9019.70
2026Q4S2026-08-1013435.711.9019.70
2026Q4S2026-08-0713335.661.9019.70
2026Q4S2026-08-0112106.151.9315.84
2026Q4S2026-07-2612116.151.9315.84

Estimate history

EPS, annual-3.53-2.164-2.154-3.553-7.7390.345-1.116-2.998-2.402-3.0806
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.255-1.111-0.519-0.338-0.495-1.034-0.949-0.837-0.261
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual12.99815.75320.7899.53912.359205.999157.748138.38967.22121.42
Period201720182019202020212022202320242025TTM
Sales, quarterly38.8152125.47724.5114.1533.0810.610.8816.852
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual10.65610.71915.13826.19226.37226.55526.8282728.41428.461
Period201720182019202020212022202320242025MRQ
Shares, quarterly27.0842727.12127.14827.23528.41428.42328.42328.461
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue21.4267.22138.39157.75206.0012.369.5420.7915.75
Cost of Goods Sold Incl. D&A2.543.033.542.96-----
Gross Profit18.8864.20134.84154.79-----
Selling, General and Administrative Excl. Other118.25139.15173.97158.94187.10208.9288.8845.6236.98
Research and Development75.8296.10124.69109.03142.55168.6666.5533.6416.98
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-99.36-74.95-39.13-4.1517.38-197.75-80.22-25.51-21.81
Interest Expense-0.000.000.773.002.670.830.850.19
Unusual Expense4.6916.1270.4649.155.205.100.00-0.00
Net Income Before Taxes-87.25-65.78-80.95-27.8911.16-204.19-71.89-25.96-21.48
Income Taxes-0.000.00-0.001.841.300.000.000.000.00
Consolidated Net Income-87.24-65.78-80.94-29.739.35-203.67-72.15-25.99-21.79
Net Income From Continuing Operations-87.24-65.78-80.94-29.739.35-203.67-72.15-25.99-21.79
Net Income-87.24-65.78-80.94-29.739.35-203.67-72.15-25.99-21.79
EPS (Recurring)-2.95-1.99-1.170.180.48-7.60-3.55-2.15-2.16
EPS (Basic, Before Extraordinaries)-3.08-2.40-3.00-1.120.35-7.74-3.55-2.15-2.16
EPS (Diluted)-3.08-2.40-3.00-1.120.35-7.74-3.55-2.15-2.16
EBITDA-96.83-71.93-35.58-1.2018.90-196.56-79.34-24.83-21.23
Non-Operating Income (Expense)16.8125.2928.6526.181.981.349.170.410.51
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense17.0820.0730.0127.3723.5728.926.761.980.96
Price To Earnings Ratio---8.72-----
Price To Sales Ratio18.172.503.315.322.2378.8192.346.312.90
Gross Margin88.1495.5097.4498.13-----
Operating Margin-463.82-111.51-28.27-2.638.44-1,600.06-841.01-122.72-138.46
Net Margin-407.24-97.86-58.49-18.844.54-1,647.98-756.35-125.02-138.29
Shares Outstanding28.4628.4127.0026.8326.5526.3726.1915.1410.72
Market Capitalization270.64270.64459.67842.59449.32975.601,121.72164.5548.64

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue16.850.880.613.0814.1524.5125.4821.00
Cost of Goods Sold Incl. D&A0.600.600.660.680.800.800.800.82
Gross Profit16.250.28-0.052.4013.3523.7124.6820.18
Selling, General and Administrative Excl. Other25.7727.5129.7335.2428.9735.2939.6039.97
Research and Development15.8817.1220.9321.8919.3825.7529.0828.41
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-9.52-27.23-29.78-32.84-15.62-11.58-14.92-19.79
Interest Expense0.000.00-0.000.000.00-0.00
Unusual Expense1.120.390.602.593.893.835.8115.37
Net Income Before Taxes-7.41-23.79-26.96-29.08-13.45-9.18-14.08-30.01
Income Taxes0.000.000.00-0.000.000.000.00-0.00
Consolidated Net Income-7.41-23.79-26.96-29.08-13.45-9.18-14.08-30.01
Net Income From Continuing Operations-7.41-23.79-26.96-29.08-13.45-9.18-14.08-30.01
Net Income-7.41-23.79-26.96-29.08-13.45-9.18-14.08-30.01
EPS (Recurring)-0.23-0.83-0.93-0.97-0.39-0.24-0.37-0.71
EPS (Basic, Before Extraordinaries)-0.26-0.84-0.95-1.03-0.49-0.34-0.52-1.11
EPS (Diluted)-0.26-0.84-0.95-1.03-0.49-0.34-0.52-1.11
EBITDA-8.91-26.63-29.12-32.16-14.82-10.78-14.12-18.97
Non-Operating Income (Expense)3.223.843.426.346.066.236.665.15
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense4.044.233.425.394.534.905.267.10
Price To Sales Ratio18.1710.205.182.565.893.212.193.31
Gross Margin96.4431.82-7.8777.8694.3596.7496.8696.10
Operating Margin-56.46-3,094.66-4,881.97-1,065.79-110.37-47.23-58.57-94.23
Net Margin-43.99-2,702.84-4,420.33-943.82-95.02-37.45-55.25-142.88
Shares Outstanding28.4628.4228.4228.4127.2327.1527.1227.00
Market Capitalization270.64191.00219.43174.17500.46352.84287.20459.67

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments230.91292.03347.00391.88370.49462.8971.3536.7148.74
Short Term Receivables5.563.9732.062.763.372.122.184.480.48
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets4.979.987.528.695.102.770.760.641.65
Total Current Assets241.45305.98386.59403.33378.96467.7974.2941.8350.87
Net Property, Plant & Equipment27.8236.2040.9344.9611.268.567.481.981.05
Total Investments and Advances1.891.891.892.092.590.110.370.400.11
Intangible Assets0.000.000.000.000.000.000.000.000.00
Deferred Tax Assets--------26.61
Other Assets0.000.000.000.000.000.000.000.000.00
Total Assets271.15344.07429.40450.39392.81476.4682.1444.2078.64
Short Term Debt Incl. Current Port. of LT Debt4.213.554.3164.5424.012.880.830.000.00
Accounts Payable4.247.195.287.4510.0610.775.792.401.79
Income Tax Payable-0.000.641.29-----
Other Current Liabilities27.9354.7471.7653.7065.4735.8714.7010.189.25
Total Current Liabilities36.3865.4981.99126.9899.5449.5221.3212.5811.04
Long Term Debt20.7825.0025.9130.2245.1317.8719.849.910.00
Provision for Risks Charges0.000.000.000.000.000.000.000.00-
Deferred Tax Liabilities--------26.61
Other Liabilities0.0012.6042.9922.8819.9312.5115.188.077.19
Total Liabilities57.16103.09150.89180.07164.6079.9056.3530.5644.84
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity213.99240.98278.51270.31228.21396.5525.7913.6433.79
Total Shareholders Equity213.99240.98278.51270.31228.21396.5525.7913.6433.79
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity213.99240.98278.51270.31228.21396.5525.7913.6433.79
Total Liabilities & Stockholders Equity271.15344.07429.40450.39392.81476.4682.1444.2078.64
Book Value Per Share7.538.9310.3810.188.6515.141.701.273.17
Tangible Book Value Per Share7.538.9310.3810.188.6515.141.701.273.17
Full-Time Employees111176180170177118887260
Price to Book Ratio1.581.763.013.084.282.876.383.560.82
Return on Assets-21.39-20.93-6.762.22-46.86-25.83-41.14-35.47-16.75
Return on Equity-28.92-31.16-10.833.75-65.20-34.17-131.82-91.85-26.91
Return on Invested Capital-28.02-30.43-9.763.11-74.51-17.41-56.95-92.49-32.26
Quick Ratio6.644.674.723.183.819.453.483.334.61
Current Ratio6.644.674.723.183.819.453.483.334.61

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-89.76-65.78-80.94-29.739.35-203.67-72.15-25.99-21.79
Depreciation2.673.033.542.961.531.190.880.680.58
Other Funds (Non Cash)22.2627.6938.461.2933.6736.217.192.881.60
Funds from Operations-64.83-35.07-38.94-25.4844.55-166.28-64.08-22.43-19.60
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital0.33-39.20-20.817.38-12.5631.2321.2215.98-1.16
Cash from Operating Activities-64.50-74.27-59.75-18.1031.99-135.04-42.86-6.45-20.76
Capital Expenditures0.04-0.23-0.65-2.90-7.73-3.41-1.74-0.82-1.48
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.050.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.0023.61
Purchase of Investments0.000.000.000.000.000.000.000.00-6.59
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.0030.21
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities0.09-0.23-0.65-2.90-7.73-3.41-1.74-0.8222.13
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock12.7313.385.423.282.141.42436.1536.960.33
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock12.7313.385.423.282.141.42436.1536.960.33
Proceedsfrom Stock Options0.000.000.000.000.410.52433.4236.820.00
Issuance or Reduction of Debt, Net0.000.000.00-27.36-5.0046.600.004.959.87
Change in Long Term Debt0.000.000.00-27.36-5.0046.600.004.959.87
Issuance of Long Term Debt0.2215.000.0020.000.0046.600.004.959.87
Reduction of Long Term Debt-0.22-15.000.00-47.36-5.000.000.00-0.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities12.7313.385.42-24.09-2.8648.02436.1541.9110.20
Net Change in Cash-51.68-61.12-54.98-45.0921.41-90.43391.5434.6411.58
Free Cash Flow-64.47-74.50-60.40-21.0024.27-138.45-44.60-7.26-22.24
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow----18.94----
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments184.82191.48211.38230.91235.36251.47
Short Term Receivables1.251.811.345.567.9517.20
Inventories0.000.000.000.000.000.00
Other Current Assets3.333.874.164.975.895.83
Total Current Assets189.40197.16216.88241.45249.20274.50
Net Property, Plant & Equipment23.8925.1226.5027.8231.2632.88
Total Investments and Advances2.032.032.031.891.891.89
Intangible Assets0.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.00
Total Assets215.32224.31245.41271.15282.34309.27
Short Term Debt Incl. Current Port. of LT Debt3.623.974.314.214.124.03
Accounts Payable5.774.414.094.245.4910.62
Other Current Liabilities18.9625.1625.9727.9322.0931.86
Total Current Liabilities28.3433.5434.3736.3831.7046.52
Long Term Debt18.2418.9719.6820.7821.8622.93
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.004.228.77
Total Liabilities46.5952.5054.0557.1657.7878.22
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity168.73171.81191.36213.99224.56231.05
Total Shareholders Equity168.73171.81191.36213.99224.56231.05
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity168.73171.81191.36213.99224.56231.05
Total Liabilities & Stockholders Equity215.32224.31245.41271.15282.34309.27
Book Value Per Share5.936.046.737.538.258.51
Tangible Book Value Per Share5.936.046.737.538.258.51
Full-Time Employees---111--
Price to Book Ratio1.581.001.030.742.171.51
Return on Assets-35.06-34.96-27.26-21.39-20.43-17.24
Return on Equity-44.37-46.31-37.01-28.92-27.43-24.57
Return on Invested Capital-3.97-12.47-12.78-12.39-5.46-3.61
Quick Ratio6.685.886.316.647.865.90
Current Ratio6.685.886.316.647.865.90

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-6.32-25.09-26.96-31.39-15.03-9.28
Depreciation0.570.680.660.760.860.79
Other Funds (Non Cash)3.874.514.299.596.716.38
Funds from Operations-1.88-19.90-22.01-21.04-7.45-2.11
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-4.18-1.022.572.96-12.17-3.82
Cash from Operating Activities-6.06-20.92-19.44-18.08-19.63-5.93
Capital Expenditures-0.050.000.000.09-0.19-0.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses-0.000.020.030.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.050.020.030.09-0.19-0.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.290.000.0212.421.300.28
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.290.000.0212.421.300.28
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.00-15.00
Change in Long Term Debt0.000.000.000.000.00-15.00
Issuance of Long Term Debt0.000.000.000.220.620.06
Reduction of Long Term Debt0.000.000.00-0.22-0.62-15.06
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.290.000.0212.421.30-14.72
Net Change in Cash-5.82-20.90-19.39-5.57-18.52-20.65
Free Cash Flow-6.11-20.92-19.44-17.99-19.82-5.93

Revenue breakdown

Collaboration2024: 138.39M 2025: 67.22M
Grant2024: 13.92M 2025: 14.81M
United States2024: 152.31M 2025: 82.03M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3020.48%5.4M26.4M981.45K
2026-10-1520.96%5.5M26.1M932.63K
2026-09-3020.65%5.4M26.1M936.68K
2026-09-1520.99%5.5M26.1M861.17K
2026-08-3123.40%6.1M26.1M777.05K
2026-08-1425.05%6.5M26.1M499.92K
2026-07-3127.67%7.2M26.1M472.28K
2026-07-1526.89%7.0M26.1M451.95K
2026-06-3026.11%6.8M26.1M425.03K
2026-06-1525.75%6.7M26.1M445.77K
2026-05-2925.83%6.7M26.1M474.29K
2026-05-1525.24%6.6M26.1M470.58K
2026-04-3024.75%6.4M26.0M461.28K
2026-04-1524.02%6.3M26.0M480.71K
2026-03-3124.78%6.5M26.0M502.13K
2026-03-1322.81%5.9M26.0M507.57K
2026-02-2723.36%6.1M26.0M545.88K
2026-02-1325.27%6.6M26.0M641.80K
2026-01-3026.45%6.9M26.0M730.24K
2026-01-1527.63%7.2M26.0M1.21M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.504.609.5012.060.0001.000.000.950-0.1000.002
call5.002.207.000.0011.7590.000.000.871-0.1070.003
call6.003.004.200.004.6100.000.000.830-0.1020.004
call7.500.104.900.006.1330.000.000.757-0.0890.005
call9.000.004.901.457.2041.000.000.641-0.1050.006
call10.000.251.450.502.90553.000.000.518-0.0850.006
call11.000.004.901.494.05375.000.000.544-0.1340.006
call12.500.004.900.254.0827450.000.449-0.1320.006
call14.000.001.300.254.3331,2070.000.402-0.1360.006
call15.000.000.500.112.9514120.000.234-0.0710.005
call16.000.004.900.003.1790.000.000.224-0.0750.005
call17.500.000.250.052.84960.000.000.136-0.0490.003
call19.000.000.950.003.0970.000.000.129-0.0510.003
call20.000.004.900.053.30536.000.000.124-0.0560.003
call22.500.004.900.003.5830.000.000.116-0.0550.003
call25.000.003.500.003.8740.000.000.111-0.0570.003
call30.000.004.900.004.4600.000.000.102-0.0660.003
put2.500.004.900.0011.8260.000.00-0.051-0.1000.002
put5.000.004.900.006.6370.000.00-0.127-0.1140.003
put6.000.004.900.005.3160.000.00-0.165-0.1090.004
put7.500.001.500.003.7370.000.00-0.238-0.0960.005
put9.000.001.100.402.03969.000.00-0.360-0.1110.006
put10.000.751.000.911.0011230.00-0.482-0.0850.006
put11.000.054.901.006.6507.000.00-0.459-0.1360.006
put12.500.655.501.405.69786.000.00-0.493-0.1580.006
put14.002.056.900.006.0560.000.00-0.598-0.1340.006
put15.003.007.903.396.35740.000.00-0.765-0.0750.005
put16.004.008.900.006.5540.000.00-0.777-0.0790.004
put17.505.5010.406.556.5730.000.00-0.864-0.0510.003
put19.008.5010.200.004.1870.000.00-0.871-0.0530.003
put20.008.0012.909.487.4000.000.00-0.875-0.0540.003
put22.5010.5015.400.007.8290.000.00-0.883-0.0570.003
put25.0013.0017.900.008.1990.000.00-0.889-0.0590.003
put30.0018.0022.900.008.8110.000.00-0.897-0.0630.003

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-058-KCurrent report2026-11-05SEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-29SCHEDULE 13G/ASEC
2026-10-07SCHEDULE 13G/ASEC
2026-09-238-KCurrent report2026-09-23SEC
2026-08-258-KCurrent report2026-08-25SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-028-KCurrent report2026-06-26SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-058-KCurrent report2026-06-05SEC
2026-05-074Statement of changes in beneficial ownership of securities2026-05-01SEC
2026-05-073Initial statement of beneficial ownership of securities2026-05-01SEC
2026-05-078-KCurrent report2026-05-01SEC
2026-05-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-07SCHEDULE 13G/ASEC
2026-04-24DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-05SEC
2026-03-26SCHEDULE 13G/ASEC
2026-03-038-KCurrent report2026-03-03SEC
2026-03-0310-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-02-17SCHEDULE 13G/ASEC
2026-02-03SCHEDULE 13G/ASEC
2026-01-08SCHEDULE 13G/ASEC
2025-12-30S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
FEDERATED HERMES, INC.11.62%
ARK Investment Management LLC10.21%
BlackRock, Inc.9.20%
Amova Asset Management Americas, Inc.6.90%
Sumitomo Mitsui Trust Group, Inc.5.94%
VANGUARD CAPITAL MANAGEMENT LLC3.92%
TWO SIGMA INVESTMENTS, LP3.84%
VANGUARD PORTFOLIO MANAGEMENT LLC3.35%
AQR CAPITAL MANAGEMENT LLC2.37%
JACOBS LEVY EQUITY MANAGEMENT, INC2.28%

Funds

Fund% owned
ARK Genomic Revolution ETF9.64%
Federated Hermes Kaufmann Fund6.90%
Federated Hermes Kaufmann Small Cap Fund4.18%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.80%
iShares Russell 2000 ETF2.51%
VANGUARD EXTENDED MARKET INDEX FUND1.03%
Fidelity Small Cap Index Fund1.03%
VANGUARD EXPLORER FUND1.01%
iShares Russell 2000 Value ETF0.89%
VANGUARD STRATEGIC SMALL-CAP EQUITY FUND0.89%

OakChart. ARCT. Cached 15 minutes.

Some panels did not load: insider.